Takeda deal looks to bolster biologics pipeline
Twist Biosciences, under its Twist Biopharma division, has formed a deal with Takeda that sees it provide access to its ‘Library of Libraries’ for antibody therapeutic discovery and optimization.
The two companies will work on the optimization of antibodies already existing in Takeda’s pipeline of biologics, including targets for oncology, rare diseases, neuroscience, and gastroenterology.
The platform that Takeda gains access to is a panel of synthetic antibody phage display libraries, which have been derived from sequences that exist in the human body.
In return for access to the tool, Takeda will pay Twist an undisclosed annual technology licensing fees, as well as potential milestone payments and royalties on all compounds discovered through the libraries.
Robert Mabry, head of global biologics research at Takeda, outlined that the partnership will allow the company to grow its pipeline of targeted biologic candidates.
This has been a focus for the company since the turn of the year, after it secured a number of licensing and partnership deals designed to build out its pipeline in areas such as gene therapy, plasma treatments, and exosome therapeutics.